UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

The recent FDA approval of sacituzumab govitecan for certain patients with triple-negative breast cancer was an exciting one. Here’s what oncology nurses need to know.

There is far less patient education for oral agents, such as CDK4/6 inhibitors for breast cancer, as there is for chemotherapy. This is a major issue, explained Patricia Jakel, MN, RN, AOCN, advanced practice nurse at UCLA's solid tumor program and co-editor in chief of Oncology Nursing News.

Frequent communication between patients and providers is key in getting ahead of adverse events that can occur during breast cancer treatment, explained Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.

A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

Wendy Sanchez, ARNP, Florida Cancer Specialists, discusses treating patients with breakthrough cancer pain.

Rowan Chlebowski, MD, PhD, discusses how losing 5 pounds, as seen in the Women's Intervention Nutrition Study, had a positive impact for breast cancer patients, especially whose disease was triple-negative.

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses palliative care and survivorship care